To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world Practice
NCT ID: NCT07029451
Last Updated: 2026-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
2500 participants
OBSERVATIONAL
2025-08-05
2028-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
There will be approximately 2500 patients initiated with REKOVELLE® treatment and enrolled in 30-50 sites in China. The total duration of the study will be approximately 35 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oxidative Stress-related Gene Expression in Cumulus Cells Among Low Responders
NCT03155438
The Effect of RECO-18 on Infertile Women Undergoing in Vitro Fertilization-embryo Transfer
NCT05412147
Automitochondrial Transplantation Improves Live Birth in Elderly Patients With Low Prognosis After Repeated IVF Failure
NCT06020742
Prospective Genetic Study in Patients With Ovarian Insufficiency
NCT03474120
The Clinical Cohort Study of Reproductive Health
NCT05164029
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 20 years of age (including the 20th birthday) when signing informed consent
* Prescribed REKOVELLE for the first time in controlled ovarian stimulation for in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycles
* Willing and able to provide written informed consent
Exclusion Criteria
* Previously undergone more than 1 controlled ovarian stimulation cycles for IVF or ICSI
* Currently participating in an interventional clinical study for which treatment with medication is mandated
* Currently undergoing ovarian stimulation for fertility preservation or oocytes donation
* Contraindications for the use of REKOVELLE
20 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ferring Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Compliance
Role: STUDY_DIRECTOR
Ferring Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Maanshan Maternal and Child Health Care Hospital
Ma’anshan, Anhui, China
Beijing Obstetrics And Gynecology Hospital Capital Medical University
Beijing, Beijing Municipality, China
Beijing Chaoyang Hospital (Beijing)
Chaoyang, Beijing Municipality, China
Peking University First Hospital
Xicheng, Beijing Municipality, China
6th Affiliated Hospital of Sun Yat Sen University
Guangzhou, Guandong, China
3rd Affiliated Hospital of Guangzhou Medical University (Guangzhou)
Guangzhou, Guangdong, China
The First Affiliated Hospital of Shantou University Medical College
Shantou, Guangdong, China
The Second Nanning People's Hospital
Nanning, Guangxi, China
Tongji Hospital Tongji Medical College of Hust
Wuhan, Hubei, China
Hubei Maternal and Child Health Hospital
Wuhan, Hubei, China
Reproductive & Genetic hospital Of CITIC-Xiangya
Changsha, Hunan, China
1st Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China
The Second Affiliated Hospital of Air Force Medical University
Xi'an, Shaanxi, China
Binzhou Medical University Hospital
Binzhou, Shandong, China
Reproductive Hospital Affiliated to Shandong University
Jinan, Shandong, China
Affiliated Hospital of Jining Medical University
Jining, Shandong, China
Shanghai First Maternal and Child Health Hospital
Shanghai, Shanghai Municipality, China
Northwest Women's and Children's Hospital
Xi’an, Shanxi, China
Tianjin Medical University General Hospital (Heping District)
Xiaobailou, Tianjin Municipality, China
Women's hospital School of Medicine Zhejiang University
Hangzhou, Zhejiang, China
Peking University Third Hospital (Beijing)
Beijing, , China
Zhejiang Provincial People's Hospital
Hangzhou, , China
Jinhua People's Hospital
Jinhua, , China
The Peoples Hospital of Guangxi Zhuang Autonomous Region
Nanning, , China
The Reproduction Hospital of Guangxi Zhuang Autonomous Region
Nanning, , China
Zhongshan Hospital Affiliated to Fudan University
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
000442
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.